What the FDA labels say about taking them together
Nicardipine and tacrolimus
Nicardipine's FDA label of August 24, 2024 names tacrolimus in its drug interactions section, and tacrolimus's label names nicardipine too. The tacrolimus label: “Monitor tacrolimus whole blood trough concentrations and reduce ASTAGRAF XL dose if needed.”
Check it at the source: the nicardipine FDA label on DailyMed (effective August 24, 2024, Hikma Pharmaceuticals USA Inc.); the tacrolimus FDA label on DailyMed (effective July 17, 2026, Stellon Biotech Inc.).
What does the nicardipine label say about tacrolimus?
Nicardipine label, drug interactionsDRUG INTERACTIONS Cimetidine increases nicardipine plasma levels ( 7.3 ). Nicardipine may increase cyclosporine and tacrolimus plasma levels.
Cardene Iv label (Baxter Healthcare Corporation, April 13, 2026), drug interactionsOral or intravenous nicardipine may increase cyclosporine and tacrolimus plasma levels.
Source: FDA drug label (Cardene Iv, NDA019734), Baxter Healthcare Corporation, effective April 13, 2026 (SPL set a3e33add-0d09-423a-9109-42e5ba7148d5), via openFDA
Source: FDA drug label (Nicardipine Hydrochloride), Hikma Pharmaceuticals USA Inc., effective August 24, 2024 (SPL set 18fb1c2b-0c1e-436c-a5b6-d4840b5da228), via openFDA; the full label on DailyMed
What does the tacrolimus label say about nicardipine?
Tacrolimus label, drug interactionsDrug/Substance Class or Name: Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see,,)].; Recommendations: Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed [ see,) and ].
Envarsus Xr label (Veloxis Pharmaceuticals, Inc, February 26, 2025), drug interactionsDrug/Substance Class or Name: Mild or Moderate CYP3A Inhibitors, such as: antibiotics (e.g., erythromycin), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole, azole antifungals (e.g., clotrimazole, fluconazole, isavuconazole), imatinib, nilotinib, letermovir; Drug Interaction Effect: May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see,, ].; Recommendations: Monitor tacrolimus whole blood trough concentrations and reduce ENVARSUS XR dose if needed [see and ].
Source: FDA drug label (Astagraf Xl, NDA204096), Astellas Pharma US, Inc., effective January 14, 2026 (SPL set 550a5cd4-fbf2-4c09-b577-6bde8fcbdf6e), via openFDA
Source: FDA drug label (Envarsus Xr, NDA206406), Veloxis Pharmaceuticals, Inc, effective February 26, 2025 (SPL set de2315b0-6344-43ac-9aea-3e3b68d828e7), via openFDA
Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nicardipine | Tacrolimus | |
|---|---|---|
| Labeled for | High blood pressure, Angina | Organ transplant rejection, Eczema (atopic dermatitis) |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.12 per capsule 20 mg capsule | $0.970 per gram 0.1% ointment |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once